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C E L L  B I O L O G Y
Autophagy induction in atrophic muscle cells requires 
ULK1 activation by TRIM32 through unanchored  
K63-linked polyubiquitin chains
M. Di Rienzo1,2, M. Antonioli1, C. Fusco3, Y. Liu4, M. Mari5, I. Orhon5, G. Refolo1, F. Germani1, 
M. Corazzari6, A. Romagnoli1, F. Ciccosanti1, B. Mandriani3, M. T. Pellico3, R. De La Torre4, 
H. Ding7, M. Dentice8, M. Neri9, A. Ferlini9, F. Reggiori5, M. Kulesz-Martin4,10, M. Piacentini1,2*, 
G. Merla3, G. M. Fimia1,11*
Optimal autophagic activity is crucial to maintain muscle integrity, with either reduced or excessive levels leading 
to specific myopathies. LGMD2H is a muscle dystrophy caused by mutations in the ubiquitin ligase TRIM32, whose 
function in muscles remains not fully understood. Here, we show that TRIM32 is required for the induction of 
muscle autophagy in atrophic conditions using both in vitro and in vivo mouse models. Trim32 inhibition results 
in a defective autophagy response to muscle atrophy, associated with increased ROS and MuRF1 levels. The pro-
autophagic function of TRIM32 relies on its ability to bind the autophagy proteins AMBRA1 and ULK1 and stimu-
late ULK1 activity via unanchored K63-linked polyubiquitin. LGMD2H-causative mutations impair TRIM32’s ability 
to bind ULK1 and induce autophagy. Collectively, our study revealed a role for TRIM32 in the regulation of muscle 
autophagy in response to atrophic stimuli, uncovering a previously unidentified mechanism by which ubiquitin 
ligases activate autophagy regulators.
INTRODUCTION
Autophagy is a catabolic process that ensures the removal of excess 
or damaged cellular components in physiological and pathological 
conditions and provides metabolic supplies when extracellular nu-
trients are scarce (1, 2). By keeping the intracellular environment 
free of harmful material, autophagy plays a key protective role in 
several human diseases (3). Hereditary myopathies are among the 
best-documented examples of the close relationship between dys-
regulated autophagy and human disorders (4). Defective autophagy 
has been observed in collagen VI–related myopathies, Duchenne mus-
cular dystrophy, and Emery-Dreifuss muscular dystrophy, while im-
paired recognition of autophagy cargos is present in the limb-girdle 
muscular dystrophy (LGMD) 1D and in myofibrillar myopathies 
(4, 5). Conversely, excessive autophagy activation characterizes the 
merosin-deficient congenital muscular dystrophy 1A (6).
Cellular alterations caused by autophagy dysregulation in mus-
cles include the presence of damaged mitochondria and enlarged 
endoplasmic reticulum, the impaired turnover of sarcomeric proteins, 
and the increased susceptibility to cell death (5). Restoration of appro-
priate autophagy levels by pharmacological or dietary approaches 
ameliorates the myopathic defects in mouse models for collagen 
VI–related and Duchenne muscular dystrophies, providing preclin-
ical evidence of the relevance of dysfunctional autophagy in these 
diseases (7–9). These studies have also uncovered the existence of 
signaling pathways that link autophagy to the proper functioning of 
muscle cell compartments, such as the extracellular matrix (through 
collagen VI and laminin-2), cytoskeleton–to–plasma membrane in-
teraction (dystrophin), and nuclear envelope (lamin A/C) (4). The 
mechanisms by which these signals converge to the autophagy 
machinery to modulate its activity, however, remain unknown.
Tripartite motif-containing 32 (TRIM32) is a member of the 
TRIM protein family, a large group of E3 ubiquitin ligases charac-
terized by the presence of a RING finger domain, a B-box domain, 
a coiled-coil region, and a variable C-terminal region (10). NHL do-
mains characterized the C terminus of TRIM32, which are involved 
in protein dimerization and substrate recognitions (11). Mutations 
in the NHL domains of the TRIM32 are causative of LGMD2H and 
sarcotubular myopathy, which are mild and severe manifestations of 
the same disorder (12). Both trim32 knock-out (KO) and knock-in 
mice carrying a disease-associated mutation have confirmed the 
myopathic phenotype as a consequence of TRIM32 dysfunction 
(13, 14) and highlighted the presence of neurological defects that 
may also contribute to the muscular disorder (13). A missense mu-
tation in the B-box domain of TRIM32 causes the Bardet-Biedl syn-
drome type 11, a disease characterized by obesity, retinal degeneration, 
genito-urinary tract malformations, and cognitive impairment, but 
not showing muscle alterations (15). In keeping with this observation, 
TRIM32 also plays a role in the regulation of processes not directly 
related to muscle function, such as immunity, neural differentiation, 
and cancer (16).
How TRIM32 mutations cause muscular dystrophy has not been 
entirely clarified. A pro-atrophy role of TRIM32 has been initially pos-
tulated on the basis of its ability to ubiquitinate actin, tropomyosin, 
troponins, α-actinin, and desmin (17, 18). TRIM32 also inhibits the 
prosurvival phosphatidylinositol 3-kinase/Akt pathway through the 
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degradation of the desmosome component plakoglobin (19). Studies on 
Trim32 KO mice have shown that TRIM32 is not necessary to trigger 
muscle atrophy, but it plays a key role in muscle regrowth after atrophy 
(20). This finding is in agreement with the observation that patients 
with LGMD2H often manifest loss of motility after prolonged immo-
bilization (21). Defective muscle regeneration was also observed in 
Trim32 KO mice upon damage induced by cardiotoxin treatment (22). 
Muscle regrowth failure after atrophy has been ascribed to the im-
paired degradation of PIAS4, a SUMO (small ubiquitin- like modifier) 
ligase that induces premature senescence (20), and of the proliferation 
inhibitor NDRG2 (23). Whether TRIM32 also plays a protective role 
in differentiated muscle cells during or after atrophy induction remains to 
be elucidated.
Recently, several members of the TRIM protein family have been 
demonstrated to promote autophagy induction by interacting with 
the upstream regulators ULK1 (Unc-51 like autophagy activating 
kinase 1) and BECLIN 1 (24–27). In addition, TRIM proteins act as 
cargo receptors for selective autophagy (27–29).
AMBRA1 (activating molecule in BECN1-regulated autophagy 
protein 1) is a positive regulator of autophagy that binds and regu-
lates BECLIN 1 and ULK1 activity (30–33) by favoring their non-
degradative ubiquitination. In addition, AMBRA1 interacts with 
the E3 ubi quitin ligases CULLIN4 and CULLIN5 (34) to regulate 
the temporal dynamics of autophagy response and, with PARKIN 
and HUWE1, to promote mitophagy (35, 36). Evidence of a role of 
AMBRA1 in muscle homeostasis have been recently reported (37). 
Ablation of AMBRA1 in zebrafish leads to a severe myopathy char-
acterized by disorganized myofibers and aberrant mitochondria 
morphology (37). Abnormal muscle structure organization was also 
observed in AMBRA1 mutant mouse embryos (37). Here, we show 
that AMBRA1 interacts with TRIM32 and mediates autophagy in-
duction in muscle cells under atrophic conditions by stimulating 
ULK1 activity via unanchored K63-linked polyubiquitin.
RESULTS
AMBRA1 interacts with the E3 ubiquitin ligase TRIM32
AMBRA1 was found in association with TRIM32 in a mass spectrometry– 
based protein interaction screening (34). The binding between AMBRA1 
and TRIM32 was confirmed by coimmunoprecipitation in 293 T cells 
expressing MYC-AMBRA1 and FLAG-TRIM32 proteins (Fig. 1A) and 
in C2.7 myoblast cells at endogenous levels (Fig. 1B). The domains of 
AMBRA1 and TRIM32 responsible for their interaction were mapped 
by means of deletion mutants. Coimmunoprecipitation experiments in 
293 T cells transfected with vectors encoding the N-terminal, central, 
or C-terminal region of AMBRA1 showed that TRIM32 preferentially 
associates with the C-terminal part of AMBRA1 (Fig. 1C). On the other 
hand, coimmunoprecipitation experiments in TRIM32 KO 293 T cells 
transfected with TRIM32 mutants encoding the catalytic domain 
(RING/B-box), the coiled-coil domain, or the NHL repeats showed 
that the catalytic domain of TRIM32 is responsible for the binding to 
Ambra1 (Fig. 1D).
TRIM32 is required for the induction of autophagy 
by atrophic stimuli
The interaction of TRIM32 with AMBRA1 prompted us to analyze 
the role of TRIM32 in the regulation of autophagy in muscle cells. 
We performed experiments in a murine myoblast cell line (C2.7 cells), 
which is able to differentiate into myotubes upon serum withdrawal. 
At first, we asked whether AMBRA1 and TRIM32 were required for 
sustaining basal autophagy in undifferentiated and differentiated cells. 
We measured autophagy flux in cells in which AMBRA1 or TRIM32 
expression was down-regulated by using specific lentiviral short 
hairpin RNAs (shRNA; shAmbra1 and shTrim32). Analysis of LC3-II 
levels in the presence or absence of lysosome inhibitors revealed 
that basal autophagy flux is defective when AMBRA1 expression is 
silenced both in myoblasts and myotubes (fig. S1A). We also observed 
a partial inhibition of the myosin heavy chain expression, accord-
ingly to the role of basal autophagy in supporting the differentia-
tion of C2 myoblasts (38). In contrast, we observed no significant 
alterations of autophagy flux in either undifferentiated or differenti-
ated cells in which TRIM32 expression was down-regulated, indicat-
ing that TRIM32 is dispensable for sustaining basal autophagy (fig. S1B).
TRIM32 was reported to play an important role in muscle fiber 
recovery from atrophic conditions (20). Since autophagy is up- 
regulated during muscle atrophy (5), we decided to investigate the 
role of TRIM32 in the induction of autophagy in response to atrophic 
stimuli. To set up the experimental conditions to induce muscle atrophy 
in vitro, we treated the differentiated C2.7 cells with dexamethasone, 
a synthetic analog of glucocorticoids, for 24 hours and verified atrophy 
induction by analyzing the expression level of the atrophic gene MuRF1 
(fig. S2A). In parallel, we evaluated autophagy flux after 4 hours of 
treatment by LC3 immunoblotting analysis, which confirmed that 
autophagy is induced by dexamethasone (fig. S2B).
Similar to that observed in basal autophagy, shAmbra1 C2.7 cells 
treated with dexamethasone showed lower LC3-II levels (fig. S2C). 
Notably, a significant impairment of autophagy induction was also 
observed when TRIM32 knock-down or KO myotubes were exposed 
to dexamethasone (Fig. 2A and fig. S2, D and E). Autophagy impair-
ment upon TRIM32 down-regulation was not restricted to C2.7 cells, 
as a similar defect was also observed in rat L6E9 myoblasts upon 
dexamethasone treatment (fig. S2F). We confirmed failure of Trim32- 
 silenced C2.7 cells to increase autophagy flux by measuring the lyso-
somal degradation rate of the autophagy cargo receptor NBR1(next 
to BRCA1 gene 1 protein) at a later time point of dexamethasone 
treatment (fig. S3A), as well as by ultrastructural analysis. In particular, 
transmission electron microscopy showed that the number of degra-
dative compartments (amphisomes, lysosomes, and autolysomes) per 
cell section, which reflects autophagic activity (39), was similar in 
untreated shControl and shTrim32 C2.7 cells (fig. S3B), corroborating 
that TRIM32 is not involved in basal autophagy. Atrophy stimulation 
in control cells led to an increased number of degradative compart-
ments per cell section, confirming autophagy induction under these 
conditions (Fig. 2B and fig. S3C, top). In contrast, no increase was 
observed in TRIM32- depleted cells exposed to dexamethasone, under-
lying that TRIM32 is required for autophagy in atrophic myotubes 
(Fig. 2B and fig. S3C, bottom).
To substantiate the involvement of TRIM32 in the regulation of 
autophagy in atrophic conditions, we analyzed autophagy flux upon 
nutrient deprivation as an alternative atrophic stimulus. Also, in this 
case, a reduced induction of autophagy was observed in TRIM32- 
silenced cells when LC3-II levels were analyzed (fig. S4A). We con-
firmed defective autophagy by measuring the lysosomal degradation 
rate of the autophagy cargo receptor p62 in shTrim32-silenced cells 
at a later time point of nutrient deprivation (fig. S4B).
We then assessed whether TRIM32 is required for an efficient 
autophagy response to atrophic stimuli in vivo using a mouse model 
of Trim32 deficiency (22). We treated Trim32 wild-type (WT) and 
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KO mice with dexamethasone for 8 hours and analyzed LC3, NBR1, 
and p62 levels in quadricep muscles by immunoblotting. As shown 
in Fig. 2C, a significant impairment of autophagy is observed in 
Trim32 KO mice upon dexamethasone treatment when compared 
to the WT counterpart. NBR1 and p62 RNA levels were also mea-
sured by quantitative polymerase chain reaction (qPCR) to rule out 
a transcriptional contribution to the observed changes (fig. S5, 
A and B). Defective autophagy response was confirmed by confocal 
microscopy as well. Quadricep muscles from WT mice treated with 
dexamethasone showed a robust increase of LC3-positive vesicles, 
which mostly colocalize with the cargo receptor p62 (fig. S5, C and 
D). Instead, the accumulation of LC3-positive vesicles was reduced 
Fig. 1. TRIM32 binds to AMBRA1. (A) Protein extracts from MYC-AMBRA1– and FLAG-TRIM32–transfected 293 T cells were subjected to immunoprecipitation (IP) using an 
anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting using anti-MYC and anti-TRIM32 antibodies. (B) Undifferentiated and differentiated 
C2.7 cells were lysed, and protein extracts were immunoprecipitated using an anti-TRIM32 antibody. An unrelated antibody was used as a negative control (IP Ctr). Immuno-
purified complexes were analyzed by immunoblotting using anti-AMBRA1 and anti-TRIM32 antibodies. (C) 293 T cells were cotransfected with vectors encoding 
HA-TRIM32 and the following MYC-AMBRA1 constructs: full length (FL), N-terminal (amino acids 1 to 532), central (amino acids 533 to 751), and C-terminal region (amino 
acids 767 to 1269). Protein extracts were immunoprecipitated using an anti-MYC antibody. Immunopurified complexes were analyzed by immunoblotting using anti-HA 
and anti-MYC antibodies. A scheme of the AMBRA1 domain architecture is shown (P-rich, proline-rich domain; S-rich, serine-rich domain; BH3, Bcl2 homology 3 domain). 
The red bar indicates the TRIM32-interacting domain. Asterisks indicate bands of AMBRA1 at the expected molecular weights. (D) TRIM32 KO 293 T cells were cotrans-
fected with vectors encoding MYC-AMBRA1 and the following FLAG-TRIM32 constructs: full length, catalytic domain (RING/B-box, amino acids 1 to 136), central region 
containing the coiled-coil domain (amino acids 136 to 326), and NHL repeats (amino acid 327 to 653). Protein extracts were immunoprecipitated using anti-FLAG anti-
body. Immunopurified complexes were analyzed by immunoblotting using anti-FLAG and anti-MYC antibodies. A scheme of the TRIM32 domain architecture is shown 
(CC, coiled-coil domain). The red bar indicates the AMBRA1-interacting domain.
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Fig. 2. Trim32 is required for autophagy induction by atrophic stimuli in muscle cells. (A) shCTR and shTrim32 C2.7 cells differentiated for 3 days were treated with 
dexamethasone (dexa) for 4 hours (h) or left untreated. One hour before lysis, cells were incubated with the lysosome inhibitors E64d and pepstatin A (E64d/PepA), as 
indicated. LC3-II and TRIM32 levels were analyzed by immunoblotting (left). GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was included as a loading control. The 
graph (right) reports means ± SD of LC3-II/GAPDH values from three independent experiments; *P < 0.05. (B) Differentiated shCTR and shTrim32 C2.7 cells were treated 
with dexamethasone for 4 hours and processed for EM. ER, endoplasmic reticulum; N, nucleus. Yellow asterisks highlight degradative compartments (amphisomes, lyso-
somes, and autolysosomes). Scale bars, 1 m. The graph (right) reports means ± SEM of degradative vacuoles per cell per section. Images of untreated cells are reported 
in fig. S3B. (C) WT (Trim32+/+) and KO (Trim32−/−)  mice were injected with dexamethasone (5 mg/kg) or saline solution (0.9% NaCl) as a negative control. Mice were sacri-
ficed 8 hours after injection, and protein extracts were prepared from quadricep muscles. LC3-II, NBR1, and p62 levels were analyzed by immunoblotting (left). Arrows 
point to TRIM32- and NBR1-specific bands; the number sign (#) indicates nonspecific signals. The graph (right) reports means ± SD of LC3-II/GAPDH, NBR1/GAPDH, and 
p62/GAPDH values from at least three independent experiments; *P < 0.05.
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in Trim32 KO mice with the residual ones, showing diminished co-
localization with p62 (fig. S5, E and F).
Autophagy inhibition is known to exacerbate muscle damage in 
response to atrophic stimuli, resulting in the accumulation of reac-
tive oxygen species (ROS) from dysfunctional mitochondria and an 
increased induction of atrophic genes (40, 41). Therefore, we assessed 
whether these alterations were associated with the autophagy impair-
ment observed upon TRIM32 inhibition. TRIM32-silenced myotubes 
and the relative controls were treated with dexamethasone, and the 
production of ROS was analyzed after 24 hours (fig. S6A), while the ex-
pression of the atrophic gene MuRF1 was monitored at 8 and 24 hours 
(fig. S6, B and C). We also treated control cells with the autophagy 
inhibitor 3-methyladenine (3MA), as a positive control of autophagy 
inhibition (fig. S6D). Concomitantly, we analyzed LC3-II levels at 
24 hours after dexamethasone treatment to confirm that autophagy im-
pairment was still present at the time points where ROS and MuRF1 levels 
were measured (fig. S6E). Results showed that both atrophy- related pa-
rameters were worsened in TRIM32-silenced cells, similar to those ob-
served in control cells exposed to 3MA. Together, these results point to 
a role of TRIM32 in the regulation of autophagy in atrophic conditions.
TRIM32 stimulates ULK1 activity in an AMBRA1-dependent 
manner through unanchored K63-linked polyubiquitin
TRIM proteins were reported to control autophagy by modulating 
the activity of BECLIN 1 and ULK1 (27). We therefore asked whether 
TRIM32 could regulate autophagy by interacting with these auto-
phagy regulators. Coimmunoprecipitation experiments performed 
in 293 T cells transfected with vectors encoding TRIM32, ULK1, 
and BECLIN 1 showed that TRIM32 efficiently interacts with ULK1 
(Fig. 3A). This interaction is specific for ULK1, since the binding with 
BECLIN 1 was not observed in the same experimental settings (Fig. 3A). 
We mapped the domain of TRIM32 responsible for ULK1 interac-
tion by immunoprecipitation of a series of TRIM32 deletion mu-
tants, which showed that TRIM32 binds ULK1 through its catalytic 
domain (Fig. 3B). On the basis of the ability of AMBRA1 to associate 
with both ULK1 and TRIM32, we asked whether AMBRA1 plays a 
role in the interaction between these proteins. Coimmunoprecipita-
tion analysis showed that the association between TRIM32 and ULK1 
is strongly affected when AMBRA1 expression is down-regulated 
(Fig. 3C), indicating that AMBRA1 is required to assemble TRIM32 
and ULK1 in a complex.
Since TRIM32 is an E3 ubiquitin ligase, we assessed whether its 
interaction with ULK1 results in an increase of ULK1 ubiquitination. 
To this aim, we analyzed degradative and nondegradative ubiquiti-
nation of endogenous ULK1 in TRIM32-transfected 293 T cells 
using K48- and K63-linked polyubiquitin chain antibodies, respec-
tively. As shown in Fig. 4A, TRIM32 triggers K63-linked ubiquitina-
tion of ULK1, while K48-linked ubiquitination remains unaltered 
(fig. S7A). The increase in ULK1 ubiquitination depends on the 
ligase activity of TRIM32, since a catalytic-inactive mutant is not 
able to trigger ULK1 ubiquitination (fig. S7B). We also confirmed the 
ability of TRIM32 to ubiquitinate ULK1 by in vitro assays using 
either recombinant or immunopurified ULK1 (Fig. 4B and fig. S7C). 
In keeping with its role in TRIM32-ULK1 complex formation, 
AMBRA1 down-regulation leads to a significant decrease of TRIM32- 
mediated ubiquitination of ULK1 (Fig. 4C).
Since TRIM32 was reported to produce both substrate-linked and free 
polyubiquitin chains (23, 42), we analyzed whether TRIM32- induced 
modification of ULK1 is due to either covalent ubiquitination or 
Fig. 3. TRIM32 associates with ULK1 in an AMBRA1-dependent manner. (A) Pro-
tein extracts from 293 T cells transfected with vectors encoding HA-TRIM32, FLAG–
BECLIN 1, and MYC-ULK1, as indicated, were subjected to immunoprecipitation 
using an anti-HA antibody. Immunopurified complexes were analyzed by immuno-
blotting using anti-FLAG, anti-MYC, and anti-HA antibodies. (B) TRIM32 KO 293 
T cells were cotransfected with vectors encoding MYC-ULK1 and the following 
FLAG-TRIM32 constructs: full length, catalytic domain (RING/B-box, amino acids 1 
to 133), central region containing the coiled-coil domain (amino acids 134 to 198), 
and NHL repeats (amino acids 199 to 325). Protein extracts were immunoprecipi-
tated using an anti-FLAG antibody. Immunopurified complexes were analyzed by 
immunoblotting using anti-FLAG and anti-MYC antibodies. A scheme of the 
TRIM32 domain architecture is shown; the red bar indicates the ULK1-interacting 
domain. (C) Control shRNA and shAmbra1 293 T cells were transfected with a vector 
encoding MYC-ULK1, alone or in combination with FLAG-TRIM32. Cells were lysed, 
and protein extracts were subjected to immunoprecipitation using an anti- FLAG 
antibody. Immunopurified complexes were analyzed by immunoblotting using 
anti-MYC and anti-FLAG antibodies. Total extracts were also probed with an anti- 
AMBRA1 antibody to verify AMBRA1 silencing.
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the binding to unanchored polyubiquitin. To this aim, we subject-
ed ubiquitinated ULK1, immunopurified from either TRIM32- 
transfected cells or an in vitro assay, to heat denaturation to disrupt 
noncovalent interactions. Immunoblotting analysis showed that the 
ubiquitination signal is lost following denaturation [Fig. 4, B and D 
(see lanes labeled as Re-IP)], indicating that ULK1 binds noncova-
lently to K63-linked polyubiquitin chains produced by TRIM32. More-
over, we observed that the interaction with the polyubiquitin chains 
is mediated by the C-terminal domain of ULK1, as shown by co-
transfecting TRIM32 with ULK1 deletion mutants (fig. S7D).
Since K63-linked ubiquitination of ULK1 stimulates its kinase ac-
tivity (31), we asked whether TRIM32 is able to promote ULK1 pro-
autophagic function. A phosphorylation analysis of the autophagic 
proteins VPS34 and BECLIN 1, two well-characterized targets of ULK1 
(43, 44), showed that ULK1 kinase activity is potentiated by TRIM32 
(Fig. 4, E and F). In line with these results, we also observed that 
overexpression of WT TRIM32, but not of the catalytic mutant C39S, 
results in an increased autophagy flux, as revealed by LC3 immuno-
blotting (fig. S7E). Together, these data indicate that TRIM32 can in-
duce autophagy by interacting with ULK1 in an AMBRA1-dependent 
manner and promoting its activity through unanchored polyubiquitin.
TRIM32 is required for ULK1 activation through K63-linked 
polyubiquitin in atrophic conditions
The ability of TRIM32 to bind and activate ULK1 through unanchored 
polyubiquitin prompted us to analyze the functional relation be-
tween TRIM32 and ULK1 in the induction of autophagy by atrophic 
stimuli. First, by coimmunoprecipitation assays performed in un-
treated and dexamethasone-treated C2.7 cells, we observed that 
atrophy induction stimulates the interaction of ULK1 with TRIM32 
(Fig. 5A), as well as its association with K63-linked polyubiquitin 
(Fig. 5B). Then, we investigated whether TRIM32 is required for the 
increased association of ULK1 to K63-linked polyubiquitin upon 
atrophy stimulation. Down- regulation of TRIM32 expression in 
C2.7 cells by RNA interference markedly reduced the amount of K63- 
linked polyubiquitin that coimmunoprecipitated with ULK1 upon 
dexamethasone treatment (Fig. 5C). Consistently, ULK1 activity was 
decreased upon TRIM32 down-regulation, as shown by analyzing 
the phosphorylation status of BECLIN 1 and ATG14 (AuTophaGy 
related 14), two ULK1 substrates (Fig. 5, D and E). Together, these 
results indicate that autophagy impairment in TRIM32- deficient 
muscle cells is associated with a defective activation of ULK1 medi-
ated by K63-linked polyubiquitin.
We also confirmed the key role of ULK1 in the response to atrophic 
stimuli by inhibiting the expression of NEDD4L, an E3 ubiquitin 
ligase that targets ULK1 to proteasome-mediated degradation (45). 
As shown in fig. S8 (A and B), NEDD4L silencing in C2.7 myoblasts 
resulted in ULK1 protein stabilization, leading to a higher autophagy 
induction by nutrient starvation.
TRIM32 pathogenic mutants are defective for ULK1 binding 
and autophagy induction
Specific mutations in TRIM32 are causative of the muscular disease 
LGMD2H (12). Since autophagy dysregulation plays an important role 
in various muscular dystrophies (4), we asked whether the disease- 
associated TRIM32 mutants have an impaired proautophagic activity. 
First, TRIM32 mutants were tested for the ability to bind ULK1 in a 
coimmunoprecipitation experiment. As shown in Fig. 6A, the bind-
ing of TRIM32 to ULK1 is severely affected by all tested pathogenic 
mutations. Since the ULK1-interacting domain of TRIM32 is differ-
ent from the NHL repeats (see Fig. 3B), where the disease-associated 
mutations are located, we decided to better elucidate the role of this 
domain in the binding to ULK1 by generating a TRIM32 mutant 
lacking the entire NHL repeats. When tested in a coimmunoprecip-
itation assay, the NHL TRIM32 mutant also failed to interact with 
ULK1 (fig. S8C), indicating that, although not sufficient for the 
binding, the NHL repeats need to be present to allow the interaction 
of TRIM32 with ULK1 in the context of the entire protein.
We also tested whether pathogenic mutations affect the interac-
tion between TRIM32 and AMBRA1. We observed that AMBRA1 is 
still able to interact with all mutants tested, suggesting that pathogenic 
mutations specifically impair the interaction with ULK1 (fig. S8D).
To verify whether the defective binding of Trim32 pathogenic 
mutants with ULK1 affects their ability to stimulate ULK1 proauto-
phagic activity, we further characterized two of them: Trim32D487N 
and Trim32R394H. First, we analyzed the levels of ULK1-associated 
polyubiquitin and of ULK1-mediated BECLIN 1 phosphorylation 
upon TRIM32 WT or mutant protein overexpression in 293 T cells. 
We found that both pathogenic TRIM32 mutants showed a reduced 
ability to promote ULK1 association to K63-linked polyubiquitin 
(fig. S8E) and BECLIN 1 phosphorylation on Ser15 (fig. S8F), con-
firming their defective ability to induce ULK1 activity.
Then, we analyzed whether the pathogenic TRIM32 mutants have 
an impaired ability to induce autophagy in response to atrophy in-
duction in myobast cells. To this aim, we complemented Trim32 KO 
C2.7 cells with retroviral vectors expressing TRIM32 WT, pathogenic 
mutants Trim32D487N and Trim32R394H, or the catalytic mutant 
Trim32C39S. We treated cells with dexamethasone and analyzed auto-
phagy flux by measuring LC3-II (Fig. 6B and fig. S9, A and B) and 
NBR1 (fig. S9C) levels in the presence or absence of lysosome inhibi-
tors. Immunoblot analysis showed that TRIM32 mutants have an 
impaired autophagic induction. Also, in this case, the inability of 
TRIM32 mutants to trigger autophagy was associated with a defective 
activity of ULK1, as shown by analyzing phosphorylation of BECLIN 
1 and ATG14 on Ser15 and Ser29, respectively (fig. S10, A and B).
Last, we evaluated whether cells obtained from a patient with 
LGMD2H show a defective autophagy response to dexamethasone- 
induced atrophy. To this aim, fibroblasts from a healthy donor (HD) 
and a patient with LGMD2H, carrying a complete gene deletion in 
one allele and a nonsense c.1837 C > T (R613X) mutation in the NHL 
domain of the other allele (46), were transdifferentiated in myoblasts 
by MYOD ectopic expression (fig. S10C). We treated cells with dexa-
methasone and analyzed LC3-II levels in the presence or absence of 
lysosome inhibitors to measure autophagic flux. Notably, autophagy 
induction by dexamethasone treatment was impaired in myotube 
cells carrying a TRIM32 mutation (Fig. 6C and fig. S10D). More-
over, in line with that observed in Trim32-silenced cells, atrophy 
induction was exacerbated in LGMD2H patient cells, as indicated 
by analyzing MuRF1 levels (fig. S10E). Together, these results show 
that disease-associated mutations affect the proautophagic function 
of TRIM32 (fig. S10F).
DISCUSSION
Autophagy is critical for muscle adaptation to sublethal cellular stress 
(47). Exercise increases autophagy levels to meet energetic demands 
and to eliminate dysfunctional cell constituents, such as mitochondria 
and sarcomere proteins, which may accumulate during contraction 
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Fig. 4. TRIM32 stimulates ULK1 activity in an AMBRA1-dependent manner through unanchored K63-linked polyubiquitin. (A) Protein extracts from FLAG-TRIM32– 
transfected 293 T cells were subjected to immunoprecipitation using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblotting to detect 
ULK1 and K63-linked ubiquitin. Total extracts were also probed with an anti-FLAG antibody to verify TRIM32 transfection. (B) In vitro ULK1 ubiquitination assay using im-
munopurified Flag TRIM32 and recombinant ULK1, HA ubiquitin, E1 Ub–activating enzyme (UBE1), and E2 Ub–conjugating enzyme (UBE2N). Reactions were also performed 
in the absence of UBE1 to verify ubiquitination reaction specificity. At the end of the reaction, ULK1 was immunopurified and ubiquitination evaluated by immunoblot-
ting using an anti-HA antibody (lanes 1 and 2). To verify whether ubiquitin was covalently linked, immunopurified ULK1 was boiled in 1% SDS after the ubiquitination 
reaction, reimmunoprecipitated (Re-IP), and analyzed by immunoblotting using anti-HA and anti-ULK1 antibodies (lanes 3 and 4). (C) shCtr or shAmbra1 293 T cells were 
transfected with a vector encoding FLAG-TRIM32 or an empty vector (−). Protein extracts were immunoprecipitated using an anti-ULK1 antibody. Immunopurified com-
plexes were analyzed by immunoblotting to detect ULK1 and K63-linked ubiquitin. Total extracts were also probed with FLAG and AMBRA1 antibodies to verify TRIM32 
transfection and AMBRA1 silencing, respectively. (D) 293 T cells were transfected with vectors encoding HA-tagged ubiquitin, FLAG-ULK1, and TRIM32, as indicated. Protein 
extracts were subjected to immunoprecipitation using an anti-FLAG antibody. Immunopurified complexes were analyzed by immunoblotting to detect K63-linked ubiquitin 
and ULK1 using specific antibodies. TRIM32 expression was also analyzed in total extracts. To verify whether ubiquitin was covalently linked, immunopurified FLAG-ULK1 
was boiled in 1% SDS, reimmunoprecipitated, and analyzed by immunoblotting using anti–K63-linked ubiquitin and anti-ULK1 antibodies. (E) 293 T cells were transfected 
with vectors encoding FLAG-VPS34, alone or in combination with HA-TRIM32. TRIM32, VPS34, and phospho-VSP34 [pVPS34; Ser249 (S249)] were analyzed by immunoblot-
ting. GAPDH was included as a loading control. (F) 293 T cells were transfected with vectors encoding FLAG–BECLIN 1, alone or in combination with HA-TRIM32. The levels 
of TRIM32, BECLIN 1, and phospho–BECLIN 1 [pBECLIN 1; Ser15 (S15)] were analyzed by immunoblotting. GAPDH was included as a loading control.
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(48, 49). Autophagy is also induced during prolonged inactivity or 
other atrophic stimuli, mainly to ensure the removal of surplus of 
organelles, such as mitochondria and sarcoplasmic reticulum, during 
muscle fiber remodeling (50). Although it contributes to muscle dis-
mantling, autophagy is considered a protective mechanism by pre-
venting the accumulation of harmful signals, such as ROS, generated 
by inoperative compartments (4).
How autophagy is regulated in muscle cells has been extensively 
investigated at a transcriptional level, highlighting the important 
role of FoxO, glucocorticoid receptors, nuclear factor B (NF-B), 
Fig. 5. TRIM32 is required for ULK1 activation through K63-linked polyubiquitin upon dexamethasone treatment. (A) FLAG-TRIM32–expressing C2.7 cells differ-
entiated for 3 days were treated with dexamethasone for 1 and 2 hours. Protein extracts were immunoprecipitated using an anti-FLAG antibody. Immunopurified com-
plexes were analyzed by immunoblotting to detect the presence of TRIM32 and ULK1 using specific antibodies. (B) C2.7 cells differentiated for 3 days were treated with 
dexamethasone for 1 and 2 hours. Protein extracts were immunoprecipitated using an anti-ULK1 antibody. Immunopurified complexes were analyzed by immunoblot-
ting to detect the presence of ULK1 and K63-linked polyubiquitin. An unrelated antibody was used as a negative control (IP CTR). (C) shCTR and shTrim32 C2.7 cells differ-
entiated for 3 days were treated with dexamethasone for 2 hours. Protein extracts were immunoprecipitated using an anti-ULK1 antibody. Immunopurified complexes 
were analyzed by immunoblotting to detect the presence of ULK1 and K63-linked ubiquitin. An unrelated antibody was used as a negative control. Total extracts were 
probed with an anti-TRIM32 antibody to verify silencing efficiency. (D) BECLIN 1 overexpressing Trim32 WT and KO C2.7 cells were differentiated for 3 days and incubated 
with dexamethasone or nutrient-deprived medium (Starv) for 2 hours. Protein extracts were analyzed by immunoblotting to measure the levels of phospho–BECLIN 1 [pBCN 1 
(Ser15)], BECLIN 1, and TRIM32. GAPDH was included as a loading control. (E) Trim32 WT and KO C2.7 cells differentiated for 3 days were incubated with dexametha-
sone for 2 hours. Cells were lysed, and protein extracts were analyzed by immunoblotting to measure the levels of phospho-ATG14 [pATG14 (Ser29)], ATG14, and TRIM32. 
GAPDH was included as a loading control.
 o
n







Di Rienzo et al., Sci. Adv. 2019; 5 : eaau8857     8 May 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 15
Fig. 6. TRIM32 pathological mutants are unable to interact with ULK1 and promote autophagy. (A) 293 T cells were transfected with a vector encoding for MYC-ULK1, 
alone or in combination with HA-TRIM32 WT, or the indicated pathogenic TRIM32 mutants. Protein extracts were subjected to immunoprecipitation using an anti-HA 
antibody. Immunopurified complexes were analyzed by immunoblotting to detect the presence of TRIM32 and ULK1. (B) TRIM32 KO C2.7 cells were infected with retro-
viruses encoding WT FLAG-TRIM32 or the indicated pathogenic TRIM32 mutants. EMPTY, TRIM32 KO C2.7 cells infected with noncoding retroviruses. Upon 3 days in 
differentiation medium, cells were treated with dexamethasone for 4 hours and incubated with the lysosome inhibitors E64d and pepstatin A for 1 hour before lysis, 
as indicated. LC3-II and TRIM32 levels were analyzed by immunoblotting using specific antibodies. GAPDH was included as a loading control. (C) Fibroblasts from a WT 
donor and a patient with LGMD2H were transdifferentiated to myoblasts by MYOD (myogenic differentiation 1) ectopic expression. Cells differentiated for 3 days were 
treated, or not, with dexamethasone for 2 and 4 hours. One hour before lysis, cells were incubated with the lysosome inhibitors E64d and pepstatin A, as indicated. LC3-II 
and myosin heavy chain (MYOSIN HC) levels were analyzed by immunoblotting (bottom panel). GAPDH was included as a loading control.
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and SMAD transcription factors (51). In contrast, the mechanisms 
by which stresses related to muscle inactivity are transduced to the 
autophagy machinery for the activation of the process remain less 
characterized.
Here, we report that the E3 ubiquitin ligase TRIM32 is required 
for the induction of autophagy in muscle cells by atrophic stimuli 
using both in vitro and in vivo models. The proautophagic activity of 
TRIM32 resides in its ability to bind to AMBRA1 and ULK1 and to 
synthesize K63-linked polyubiquitin chains that bind noncovalently 
to ULK1 to promote its activity (fig. S10F).
Unanchored polyubiquitin chains are known to play a key role 
in the regulation of kinase activity (52). Most evidence come from 
studies on innate immune pathways, showing that transforming growth 
factor –activated kinase 1 (TAK 1), inhibitor of nuclear factor B kinase  
(IKK), and NF-kappa-B essential modulator (NEMO) can be activated 
by the noncovalent interaction with polyubiquitin chains, which result 
in changes of the structural conformation and/or the interaction 
partners of these kinases (53–55). In this context, TRIM E3 ligases are 
emerging as key players (56), as shown for TRIM5, TRIM6, TRIM25, and 
TRIM32, with the latter adopting this strategy to activate NEMO in re-
sponse to cytosolic double- stranded DNA (42). Here, we show that 
the unanchored polyubiquitin chains are also involved in the regula-
tion of the autophagic process. TRIM32 synthesized K63-linked ubiqui-
tin chains associated with ULK1 via its C-terminal domain, resulting in 
an augmented phosphorylation of its substrates BECLIN 1 and VPS34. 
In contrast to that reported for other TRIMs, we did not observe an 
increased interaction between ULK1 and BECLIN 1 complexes upon 
TRIM32 activation, suggesting that the binding with the polyubiquitin 
chains stimulates ULK1 activity rather than favoring protein complex 
interactions.
Our data also highlighted the central role of AMBRA1 in con-
veying multiple ubiquitin signals to the autophagy machinery for 
its activation in specific cellular contexts. In atrophic muscle cells, 
AMBRA1 acts as an essential cofactor, being required for both the 
interaction and the ubiquitination of ULK1 by TRIM32. AMBRA1 
was previously shown to regulate ULK1 activity by mediating its 
covalent ubiquitination by the E3 ligase TNF receptor associated 
factor 6 (TRAF6) (31). Although the function of TRAF6 and TRIM32 
may appear redundant in autophagy regulation, these proteins play op-
posite roles in the activation of the atrophy program (20, 57, 58). 
TRAF6 inactivation significantly impairs the induction of MuRF 
expression under atrophic conditions due to its role in the activation 
of the NF-B pathway (57). Conversely, TRIM32 down-regulation 
leads to higher MuRF1 induction in myoblasts treated with dexa-
methasone, consistent with that observed when autophagy genes 
are deleted (40).
An important role of TRIM32 in muscle atrophy has been attributed 
to its ability to inhibit premature senesce of satellite cells responsi-
ble for muscle regrowth in vivo (20). Our results showing a defective 
muscle autophagy in atrophic conditions suggest that, in addition 
to regulating stem cells, TRIM32 may also contribute to the pres-
ervation of the function of differentiated muscle cells by reducing 
ROS accumulation and MuRF1 expression.
Evidence that the alteration of TRIM32-dependent autophagy 
may have an important implication in LGDM2H is underlined by 
two sets of data. First, we detected defective autophagy in myoblasts 
derived from fibroblasts of a patient with LGDM2H. Second, we 
found that disease-associated mutants of TRIM32 are unable to in-
teract with ULK1 (their binding to AMBRA1, however, is unaffected) 
and to induce autophagy in muscle cells upon dexamethasone treat-
ment, which is accompanied with accumulation of the autophagy 
cargo receptors NBR1 and p62, higher induction of MuRF1, and 
increased ROS production (fig. S10F). Further studies are required 
to clarify the molecular basis of this alteration, since the NHL repeats, 
where pathological mutations are located, do not mediate the inter-
action of TRIM32 with ULK1, which occurs through the RING/B-box 
region. We found that a TRIM32 mutant lacking the NHL repeats is 
also unable to bind ULK1, suggesting that this domain is essential to 
making the RING/B-box domain accessible to the targets in the pres-
ence of the coiled-coil region.
In conclusion, we have identified TRIM32 as an E3 ubiquitin ligase 
that regulates ULK1 activity in muscles under atrophy conditions, 
highlighting a novel autophagy pathway with potential relevance in 
human disorders. In light of these results, it is predictable that the pro-
autophagic activity of TRIM32 could be relevant in other TRIM32- 
regulated processes, such as neuronal development, tumorigenesis, 




293 T cells (American Type Culture Collection) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich, 
D6546), supplemented with 10% fetal bovine serum (Gibco, 10270), 
2 mM l- glutamine, and 1% penicillin/streptomycin solution (Sigma- 
Aldrich, G7513; P0781) at 37°C under 5% CO2. Murine myoblast 
C2.7 cells (61), rat myoblast L6E9 cells (62), and human fibroblast–
derived myoblast cells from an HD and a patient with LGMD2H 
were cultured in DMEM, supplemented with 20% fetal bovine 
serum, 2 mM l- glutamine, and 1% penicillin/streptomycin solution 
at 37°C under 5% CO2. Myoblast differentiation was induced by 
culturing cells in DMEM supplemented with 2% horse serum (Life 
Technologies, 16050122), 2 mM l-glutamine, and 1% penicillin/
streptomycin for an indicated amount of time. Fibroblasts from an 
HD and a patient with LGMD2H were provided by the Telethon 
Network of Genetic Biobanks project no. GTB12001. To prepare 
fibroblasts, a patient’s skin biopsy was obtained after informed 
consent and approval of the Ethics Committee of the University of 
Ferrara. No cell lines used in this study were found in the database 
of commonly misidentified cell lines maintained by the Interna-
tional Cell Line Authentication Committee and National Center for 
Biotechnology Information biosample. Cells were screened for myco-
plasma contamination by PCR (ABMgood, G238).
To evaluate autophagy, C2.7 cells and HD/LGMD2H-differentiated 
myoblasts were treated with 400 M dexamethasone (Calbiochem, 
265005) in the presence or absence of E64d/pepstatin A (5 g/ml) 
(Santa Cruz Biotechnology, sc-201280A and sc-45036) or 5 nM 
Bafilomycin A1 (Sigma-Aldrich, B1793) or incubated with nutrient- 
deprived medium Earle's balanced salt solution (Sigma-Aldrich, 
E2888) for the indicated time, according to guidelines. The autophagy 
inhibitor 3MA (Sigma-Aldrich, M9281) was used at 5 mM.
Myoblasts transdifferentiation
Myoblast preparation was obtained by transducing human fibroblasts 
from healthy or Trim32 mutant patients with the lentivirus cytomeg-
alovirus (CMV) MyoD-ER(T) (Addgene) with a multiplicity of infection 
of 20 and treated with 1 M 4OH-tamoxifen (Sigma- Aldrich, H7904) 
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to activate MyoD-ER(T). The transdifferentiation was confirmed by 
PCR analysis of MyoD and myogenin expression. Autophagy analysis 
was performed in the absence of 4OH-tamoxifen.
Animal studies
Trim32 KO mice were previously described (22). TRIM32 KO and 
WT mice were maintained and treated according to approved pro-
tocols and in accordance with the institutional and national guide-
lines and regulations (IP00001489) approved by the Oregon Health 
and Science University. To analyze the autophagy response to dexa-
methasone, 3-month-old mice (n = 4 for each genotype) were in-
jected subcutaneously with dexamethasone sodium salt (5 mg/kg; 
Sigma- Aldrich, D-1756) and prepared in a saline solution (vehicle, 
0.9% NaCl). The control group received an injection of saline solu-
tion (vehicle, 0.9% NaCl). Eight hours after injection, mice were 
sacrificed, and quadricep muscles were harvested and deep-frozen 
in liquid nitrogen before storing at −80°C for subsequent protein 
extraction. For immunoblotting analysis, frozen muscles were crushed 
into a fine powder with a hammer, resuspended in the extraction 
buffer (Coimmunoprecipitation Kit, Thermo Fisher Scientific, 14321D), 
supplemented with protease, phosphatase, and deubiquitinase in-
hibitors as described above, homogenized using a Dounce homoge-
nizer, incubated at 4°C for 30 min, and centrifuged at 13,000 rpm 
for 10 min to remove debris. Same amounts of total protein (30 g 
per well) were loaded on SDS–polyacrylamide gel electrophoresis 
(PAGE) for immunoblotting analysis.
Transfection and viral infection
293 T cells were transiently transfected with expression vectors using 
the calcium phosphate method, as previously described (32). For ret-
roviral production, packaging cells [293 gp/bsr (gag-pol/blasticidin 
S-resistant gene)] were cotransfected with 15 g of retroviral vectors 
and 5 g of pCMV-VSV-G using the calcium phosphate method. 
For lentiviral production, 293 T cells were cotransfected with 10 g 
of lentiviral vectors, 2.5 g of pCMV-VSV-G, and 7.5 g of psPAX2 
plasmid by using the calcium phosphate method. After 48 hours, the 
supernatant containing the retroviral or lentiviral particles was re-
covered, ultracentrifuged at 19,800 rpm on an SW28 rotor for 2 hours, 
and resuspended in phosphate- buffered saline (PBS) (500 l for 
20 ml of supernatant). Cells were infected with 80 l of viral suspen-
sion in a medium supplemented with polybrene (4 g/ml) for 8 hours. 
Two consecutive rounds of infections were performed to improve 
efficiency.
To establish Trim32 KO cells for mutant complementation assays, 
C2.7 cells were transiently transfected with CRISPR-Cas9 vectors by 
Lipofectamine LTX and Plus Reagent (Invitrogen, 15338-100), as indi-
cated by the supplier. Transduced cells were incubated with puromycin 
dihydrochloride (2.5 g/l; Santa Cruz Biotechnology, sc-108071) 
for only 48 hours to select transfected cells, where inactivation of 
Trim32 CRISPR-Cas9 has occurred, and then cultured in the ab-
sence of puromycin to avoid selecting cells with a stably integrated 
CRISPR- Cas9 vector.
Plasmids
pCDNA3 hemagglutinin (HA)–Trim32 had been previously de-
scribed (10). The HA-Trim32 mutants that correspond to human 
complementary DNA (cDNA) pathogenic Trim32 mutations were 
engineered with the QuickChange Site-Directed Mutagenesis Kit 
(StrateGene).
All retroviral constructs were based on a modified version of a 
pLPCX vector (Clontech) (32). pLPCX plasmids encoding FLAG- and 
MYC-WT AMBRA1, MYC-AMBRA1 mutants (amino acids 1 to 
532, 533 to 751, and 761 to 1269), and FLAG–BECLIN 1 were pre-
viously described (30–32). pLPCX FLAG-TRIM32 and pLPCX 
TRIM32 were obtained by subcloning from pCDNA3 HA-TRIM32. 
pLPCX FLAG-TRIM32 deletion mutant RING/B-box (amino acids 
1 to 136), coiled-coil domain (amino acids 136 to 326), NHL re-
peats (amino acids 327 to 653), and NHL (amino acids 1 to 325) 
were created using the appropriate oligonucleotides and amplifi-
cation, followed by in-frame insertion into the pLPCX FLAG vector. 
pCDNA3 HA-Trim32 C39S was generated by site-specific muta-
genesis; pLPCX FLAG-TRIM32 C39S was obtained by subcloning 
from pCDNA3 HA-TRIM32 C39S. pLPCX FLAG-ULK1 and pLPCX 
MYC-ULK1 was obtained by subcloning from pcDNA3 Myc-tag 
ULK1 (31). pLPCX FLAG-ULK1 deletion mutants (amino acids 1 to 
828 and 829 to 1050) were created using appropriate oligonucleotides 
and amplification, followed by in-frame insertion into the pLPCX 
FLAG vector. pRK5 HA-UBIQUITIN was obtained from Addgene 
(#17608). A CRISPR-Cas9 All-in-One lentiviral vector specific 
for human TRIM32 and murine TRIM32 [hTRIM32 single-guide 
RNA (sgRNA), K2465605; mTRIM32 sgRNA, K3452705] and 
control sgRNA (scramble sgRNA, K010) were purchased from 
ABMgood.
For stable murine Trim32 mRNA interference, two lentiviral Trim32 
mRNA–targeting pLKO.1 plasmids were used (TRCN0000040831 
and TRCN0000040832; Sigma-Aldrich). For stable murine Ambra1 
mRNA interference, two lentiviral Ambra1 mRNA–targeting pLKO.1 
plasmids were used (TRCN0000189905 and TRCN0000189940; 
Sigma- Aldrich). For stable human AMBRA1 mRNA interference, a 
lentiviral AMBRA1 mRNA–targeting pLKO.1 plasmid was used 
(TRCN0000168652; Sigma-Aldrich). For stable murine Nedd4L 
mRNA interference, a lentiviral Nedd4L mRNA–targeting pLKO.1 
plasmid was used (TRCN0000086870; Sigma-Aldrich). A pLKO.1 
containing a nonmammalian shRNA was used as a negative control 
(Sigma-Aldrich).
Antibodies
The primary antibodies used in this study were rabbit anti-HA 
antibody (Sigma-Aldrich, H6908), rabbit anti-FLAG antibody (Sigma- 
Aldrich, F7425), mouse anti-MYC antibody [Santa Cruz Biotech-
nology, sc-40 (9E10)], rabbit anti-MYC antibody (Millipore, 06-549), 
rabbit anti–BECLIN 1 [Santa Cruz Biotechnology, sc-11427 (H-300)], 
goat anti–BECLIN 1 [Santa Cruz Biotechnology, sc-10086 (D-18)], 
rabbit phospho–BECLIN 1 (Ser15) [Cell Signaling Technology, 
138255 and 84966 (D4B7R)], rabbit anti- ATG14 [Cell Signaling 
Technology, 96752 (D1A1N)], rabbit phospho- ATG14 [Cell Sig-
naling Technology, 13155 (S29)], rabbit anti-NBR1 (Novus Biolog-
icals, NBP1-71703), LC3 (Cell Signaling Technology, 27755), 
mouse anti–human AMBRA1 [Santa Cruz Biotechnology, sc-398204 
(G6)], rabbit anti–human AMBRA1 (Novus Biologicals, 26190002), 
rabbit anti- mouse Ambra1 (Millipore, ABC131), mouse anti– multi 
ubiquitin (MBL International, ST1200), rabbit anti–K63-linked 
ubiquitin (Millipore, 05-1308), rabbit anti–K48-linked ubiquitin 
(Millipore, 05-1307), rabbit anti-ULK1 [Santa Cruz Biotechnology, 
sc-33183 (H240)], rabbit anti-ULK1 [Cell Signaling Technology, 80545 
(D8H5)], rabbit anti- TRIM32 (Thermo Fisher Scientific, PA5-22316), 
rabbit anti–phospho- VPS34 (Ser249) (Cell Signaling Technology, 
138575), rabbit anti- VPS34 (Life Technologies, 382100), mouse 
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anti-GAPDH (glyceraldehyde- 3-phosphate dehydrogenase) (Millipore, 
CB1001), and mouse monoclonal myosin heavy chain antibody MF20 
(Novus Biologicals, MAB4470).
Immunoprecipitation and immunoblotting assays
Coimmunoprecipitation was performed by lysing cells in tris buffer 
[10 mM tris (pH 8.0) (Santa Cruz Biotechnology, sc-3715A), 150 mM 
NaCl (Sigma-Aldrich, S7653), 10% glycerol (Sigma-Aldrich, G7757), 
0.5% NP-40 (Sigma-Aldrich, 56741)] or in CHAPS buffer, in the case 
of ULK1, as previously described (31). Radioimmunoprecipitation 
assay (RIPA) buffer [150 mM NaCl (Sigma-Aldrich, S7653), 1% NP-40 
(Sigma-Aldrich, 56741), 0.5% deoxycholic acid (MP Biomedicals, 
101496), 0.1% SDS (Sigma-Aldrich, L3771), 50 mM tris (pH 8.0) 
(Santa Cruz Biotechnology, sc-3715A), and 2 mM MgCl2 (Sigma- 
Aldrich, M8266)] was used to analyze ubiquitination levels of immu-
noprecipitated proteins and for immunoblotting assays. Lysis buffer 
was complemented with protease and phosphatase inhibitors [Pro-
tease Inhibitor Cocktail plus (Sigma-Aldrich, P8340), 5 mM sodium 
fluoride (Sigma-Aldrich, S-7920), 0.5 mM sodium orthovanadate 
(Sigma-Aldrich, S6508), 1 mM sodium molibdate (Sigma- Aldrich, 
S-6646), 50 mM 2-chloroacetamide (Sigma-Aldrich, C0267), 2 mM 
1,10-phenanthroline monohydrate (Sigma-Aldrich, 320056), and 
0.5 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich, P7626)]. Co-
immunoprecipitation was performed with 1 mg of protein extracts 
from transfected cells or 3 mg in the case of endogenous proteins 
assays. For endogenous protein immunoprecipitation, protein 
extracts were incubated overnight with 2 g of antibody, and immu-
nocomplexes were recovered using 25 l of Protein A Sepharose 
(GE Healthcare, GE 17-1279-01). For immunoprecipitation of over-
expressed tagged proteins, protein extracts were incubated with 25 l 
of anti-FLAG, anti-HA, or anti-MYC antibodies conjugated to agarose 
beads (Sigma-Aldrich: A22220, A2095, and A7470, respectively) for 
2 hours. To test the covalent binding of polyubiquitin chains to ULK1, 
in the first-round immunoprecipitation assay, cell extracts were pre-
pared as described above, and then, lysates were incubated with the 
anti-FLAG antibody conjugated to agarose beads for 2 hours. 
Immuno precipitates were washed three times with RIPA buffer. Before 
the second-round immunoprecipitation assay, the immunoprecipi-
tates were denatured by boiling for 5 min at 95°C in the lysis buffer 
containing 1% SDS. The eluates were then diluted 1:10 with lysis buffer 
and reimmunoprecipitated with the anti-FLAG antibody conjugated 
to agarose beads for 2 hours.
Immunocomplexes were separated on NuPAGE bis-tris gels (Life 
Technologies, 4 to 12% EA0378BOX and 3 to 8% NW04120BOX) 
and electroblotted onto nitrocellulose (Whatman Amersham, 10600041) 
or polyvinylidene difluoride (Millipore, IPVH20200) membranes. 
Detection was achieved using horseradish peroxidase–conjugated 
secondary antibodies [anti-goat 705-036-147, anti-rabbit 711-036-
152, and anti-mouse 715-036-150 (Jackson ImmunoResearch Labora-
tories)] and enhanced chemiluminesence (ECL) [Immobilon Classico 
WBLUC0500 and Immobilon Crescendo Western HRP substrate 
WBLUR0500 (Millipore)]. Signals were acquired using Amersham 
Hyperfilm ECL (GE Healthcare, 28-9068-37) or a ChemiDoc imaging 
system.
Ubiquitination assay
293 T cells were independently transfected with plasmids encoding 
MYC-ULK1 or FLAG-TRIM32. Forty-eight hours later, cells were 
lysed in RIPA buffer for ULK1 purification and tris buffer for TRIM32 
immunoprecipitation, both containing protease inhibitors, as pre-
viously indicated. Lysates were cleared by centrifugation and sub-
jected to immunoprecipitation for 2 hours using agarose-coupled 
antibodies against MYC or FLAG tags. TRIM32 protein was eluted 
for 1 hour by means of FLAG peptide (Sigma-Aldrich, F3290) at 
400 ng/l in the 1X Ubiquitin Conjugation Reaction Buffer (Boston 
Biochem, B-70). The ubiquitination assays were performed in 100 l 
of reaction volume, combining 20 l of immunopurified MYC-ULK1 
bound to agarose-beaded Myc antibody, 20 l of eluted TRIM32, 
and the following recombinant components: 100 nM E1 Ub– 
activating enzyme (Ube1; Boston Biochem, E-305), 1 M E2 Ub–
conjugating enzyme (Ube2N; Boston Biochem, E2-664), and 50 M 
HA-ubiquitin (Boston Biochem, U-110) resuspended in Ubiquitin 
Reconstitution Buffer (Boston Biochem, B-90). In some in vitro 
ubiquitination experiments, recombinant ULK1 protein (Signal-
Chem, U01-11G) was used instead of the immunopurified one. The 
reaction was performed in 1X Ubiquitin Conjugation Reaction 
Buffer, supplemented with Mg2+–adenosine triphosphate (Boston 
Biochem, B-20) at 2 mM and incubated at 30°C for 2 hours in a rock-
ing platform. When indicated, a denaturation step was added as pre-
viously described, followed by a reimmunoprecipitation of ULK1 
using the rabbit anti-ULK1 H240 antibody (Santa Cruz Biotech-
nology, sc-33183). The incorporation of ubiquitin was analyzed by 
immunoblotting using rabbit anti-HA antibody (Sigma-Aldrich, 
H6908) to detect HA-ubiquitin.
Real-time PCR
Real-time PCR was performed, as previously described (63). Briefly, 
RNA was extracted by using a TRIzol reagent (Invitrogen, 15596-018). 
cDNA synthesis was generated using a reverse transcription kit 
(Promega, A3500), according to the manufacturer’s recommenda-
tions. qPCR reactions were performed with the Rotor-Gene 6000 
(Corbett Research Ltd.) thermocycler. The Maxima SYBR Green/
ROX qPCR Master Mix (Thermo Fisher Scientific, K0253) was used 
to produce fluorescently labeled PCR products during repetitive cy-
cling of the amplification reaction, and the melting curve protocol 
was used to check for probe specificity, as described previously (30). 
The following primer sets for all amplicons were designed using the 
Primer-Express 1.0 Software System (Roche): mouse MuRF1 forward 
(5′-CCAAGGAAAGAGCAGTATGG-3′) and reverse (5′-GCAG-
CTCTCTGGGTTATTG-3′), mouse p62 forward (5′-TGAAACAT-
GGACACTTTGGCTGGC-3′) and reverse (5′-ACATTGGGATC-
TTCTGGTGGAGCA-3′), mouse NBR1 forward (5′-GAGATG - 
AGAGGGAGGAGATT-3′) and reverse (5′-CTTCAGAGGAAG-
CAGAAGAC-3′), mouse GAPDH forward (5′-TTCAACGGCA-
CAGTCAAG-3′) and reverse (5′-CCAGTAGACTCCACGACATA-3′), 
human MYOD forward (5′-CACA ACGG ACGACTTCTATG-3′) 
and MYOD reverse (5′-GTGCTCTTCGGGTTTCAG-3′), human 
MYOG forward (5′-GCGTGTAAGGTGTGTAAGAG-3′) and 
MYOG reverse (5′-GCCTCATTCACCTTCTTGAG-3′), and human 
GAPDH forward (5′-CGCTTCGCTCTCTGCTCCT-3′) and reverse 
(5′- CCGTTGACTCCGACCTTCAC-3′).
Flow cytometry
Staining for mitochondria was performed by incubating differenti-
ated C2.7 cells with 5 M CellROX Deep Red Reagent (Thermo 
Fisher Scientific, C10422), following the manufacturer’s protocols, 
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Muscle tissue analysis by fluorescent microscopy
To analyze the autophagy response to dexamethasone, 6-month-old 
mice (n = 4 for each genotype) were injected subcutaneously with 
dexamethasone sodium salt (5 mg/kg; Sigma-Aldrich, D-1756) and 
prepared in a saline solution (vehicle, 0.9% NaCl). The control group 
received an injection of saline solution (vehicle, 0.9% NaCl). Twenty- 
four hours after injection, mice were sacrificed, and quadriceps were 
fixed with 4% formaldehyde for 24 hours at room temperature, and 
after dehydration with a series of alcohol-xylene dilutions, the tissue 
was embedded in paraffin and cut into 7-m sections. Sections were 
then dewaxed and boiled for 8 min in preheated 10 mM citric acid 
retrieval buffer (pH 6.0). Sections were subsequently blocked in PBS 
containing 1% goat serum and 0.4% Triton X-100 for 1 hour before 
the primary antibody incubation in PBS containing 0.1% Tween 20 
overnight at 4°C. Nuclei were stained with Hoechst 33342 (Sigma-Aldrich) 
during the incubation with the secondary antibody in PBS contain-
ing 0.1% Tween at room temperature for 1 hour. Fluorescent micros-
copy was performed at room temperature using the DeltaVision RT 
fluorescence microscope (Applied Precision, Issaquah, WA) equipped 
with a CoolSNAP HQ camera (Photometrix, Kew, Australia). Images 
were generated by collecting stacks of images with focal planes 0.30 m 
apart and subsequently deconvolved using the SoftWoRx software 
(Applied Precision). The following antibodies were used: rabbit anti-LC3 
(PM036; MBL International, Woburn, MA), guinea pig anti-p62 
(GP62-C; Progen, Darra, Australia), Alexa Fluor 568–conjugated goat 
anti–guinea pig immunoglobin G (IgG; Thermo Fisher Scientific, 
A-11075), Alexa Fluor 488–cojugated goat anti-rabbit IgG (H + L) 
(Thermo Fisher Scientific, A27034).
Electron microscopy
Differentiated C2.7 cells carrying control or TRIM32-targeting 
shRNA were incubated with 400 M dexamethasone for 4 hours. Cells 
were fixed before and after dexamethasone treatment by direct addi-
tion of 5% glutaraldehyde (Merck Millipore, 1042390250) and 4% 
paraformaldehyde (Sigma-Aldrich, 441244) in 0.1 M cacodylate buf-
fer (pH 7.4; Sigma-Aldrich, 20840-100G-F) to the culture medium. 
After a 20-min incubation at room temperature, the fixation solution 
was replaced by 2.5% glutaraldehyde and 2% paraformaldehyde in 
0.1 M cacodylate buffer (pH 7.4), and fixation was prolonged over-
night. Cells were then embedded in EPON resin [for 25 ml, 12 g of 
glycid ether (SERVA, 21045.02), 8 g of 2-dodecenysuccinic acid an-
hydride (SERVA, 20755.02), 5 g of methylnadic anhydride (SERVA, 
29452.02), and 560 l of N-benzyldimethylamine (Electron Miscros-
copy Sciences, 11400-25)]. Subsequently, 55-nm sections were cut 
and stained with uranyl acetate and lead citrate. Cell sections were 
examined using an 80-kV CM100 transmission electron microscope 
(Phillips). Three different grids with sections obtained from the same 
preparations were statistically evaluated. For every grid, the average 
number of degradative compartments (amphisomes, autolysosomes, 
and lysosomes) per cell section was determined by counting 25 ran-
domly selected cell profiles.
Statistical analysis
Statistical analysis of electron miscroscopy data was analyzed using the 
Mann-Whitney test (independent samples and two-sided; GraphPad). 
Statistical analysis of immunoblotting, PCR, and fluorescence- 
activated cell sorting (FACS) data were performed using unpaired, 
two-tailed Student’s t test (Excel software). Values are shown as 
means ± SD of at least three independent experiments. P values 
<0.05 were marked by an asterisk. Densitometric analysis of immuno-
blots was performed using the Adobe Photoshop software. The con-
trol ratio was arbitrarily defined as 1.00. Normal distribution was 
assumed on the basis of the appearance of the data, since n < 5. No 
statistical method was used to predetermine sample size for animal 
studies. The animal experiments were not randomized. The investi-
gators were not blinded to allocation during experiments and outcome 
assessment. No exclusion criteria were applied to exclude samples 
or animals from analysis.
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